News & Media.

Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and drugs for optical surgical navigation, announced today that it has initiated the Phase 3 portion of its pivotal study evaluating the investigational ZW800-1 (nizaracianine triflutate) to highlight the ureter during abdominopelvic surgery.

Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, announced completion of a Series A2 funding round, securing $10.5M to advance early stage development for its lead programs.

Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, announced the initiation of a pivotal study evaluating its investigational imaging-guided drug ZW800-1 (nizaracianine triflutate) to highlight the ureter during abdominopelvic surgery.